Downloads: 2 | Monthly Hits: ⮙1
Review Papers | Pharmaceutical Science | Indonesia | Volume 11 Issue 3, March 2022
PfSPZ Malaria Vaccine
Dwi Ayu Fani Novitasari
Abstract: Malaria is a disease caused by parasites. As we know that parasites have 3 life cycles while it?s on the human host: pre-erythrocytes phase, blood-stage phase, and transmission-blocking phase. As for now, the medicine for malaria disease is artemisin combination therapy which is going to be resistant, so people try to develop a vaccine for malaria to meet the goal of malaria eradication. One of the vaccines developed is RTS,S/AS01. RTS,S/AS01 is pre-erythrocytic vaccine that confers efficacy against controlled human malaria infection in about 22% in healthy malaria 5 months after vaccination. In clinical trial phase 3, RTS,S/AS01 was 26% in young infants and 36% in children (Ishizuka et al., 2016). Eradication of malaria needs vaccine protection of more than 80% and has protective efficacy for more than 6 months. Therefore, the development of a malaria vaccine is still needed. Another malaria vaccine is PfSPZ. PfSPZ is pre-erythrocytic stage vaccine similar to RTS,S/AS01. It is whole attenuated sporozoite Plasmodium falciparum.
Keywords: vaccine, malaria, PfSPZ
Edition: Volume 11 Issue 3, March 2022,
Pages: 76 - 77
How to Cite this Article?
Dwi Ayu Fani Novitasari, "PfSPZ Malaria Vaccine", International Journal of Science and Research (IJSR), https://www.ijsr.net/get_abstract.php?paper_id=SR22315171651, Volume 11 Issue 3, March 2022, 76 - 77, #ijsrnet
How to Share this Article?
Similar Articles with Keyword 'vaccine'
A Concise Review on Liposomes: A Novel Approach